Roche, NICE in Avastin data standoff

It's another blow for Roche's Avastin the U.K. The National Institute for Clinical Health and Excellence shot down the high-tech cancer med as a first-line treatment for lung and breast cancer, meaning the National Health Service won't pay for it. That's the second rejection at NICE for Avastin, which was also denied for colon cancer use.

The negative verdict came after NICE asked Roche for more data on the drug's clinical and cost-effectiveness--and Roche refused, figuring the data would just show that Avastin was too expensive to meet the agency's requirements. With the announcement came the expected rhetorical clash. "Other healthcare systems seem to think it's fairly priced," a Roche spokesman sniffed. NICE's chairman sniped, "Roche would rather not supply the drug in the U.K. than risk a negative opinion."

Avastin's thumbs-down comes at a time when expensive cancer meds are under increasing scrutiny in the U.K. And because NICE tends to be influential in the drug-reimbursement world, that scrutiny could follow cancer treatments to other countries, too.

- check out NICE's statement
- get the news from Interactive Investor
- see the Financial Times story

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.